Research programme: antiviral vaccines - Vaxart

Drug Profile

Research programme: antiviral vaccines - Vaxart

Alternative Names: Hepatitis B vaccine - Vaxart; Herpes simplex virus vaccine - Vaxart; Human papillomavirus vaccine - Vaxart; Zika virus vaccine - Vaxart

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Vaxart
  • Class Hepatitis B vaccines; Papillomavirus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Herpes simplex virus type 2 infections; Zika virus infection
  • No development reported Hepatitis B; Herpes simplex virus infections; Human papillomavirus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Herpes-simplex-virus-infections in USA (PO)
  • 03 Mar 2016 Preclinical trials in Zika virus infection (Prevention) in USA (PO)
  • 30 Oct 2015 No development reported - Preclinical for Human papillomavirus infections (Prevention) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top